Safety and Efficacy of SPD503 in Treating ADHD in Children and Adolescents Aged 6-17

Summary

The purpose of this study is to determine the efficacy of SPD503 compared to placebo in the treatment of children and adolescents aged 6-17 with ADHD.

Timeline

Start

2004-03-30

Primary completion

2004-10-07

Completion

2004-10-07

Publications

• Results Sallee FR, McGough J, Wigal T, Donahue J, Lyne A, Biederman J; SPD503 STUDY GROUP. Guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder: a placebo-controlled trial. J Am Acad Child Adolesc Psychiatry. 2009 Feb;48(2):155-65. doi: 10.1097/CHI.0b013e318191769e.

Drugs

Indications